Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Holdings Co Ltd, focuses on the research, development, manufacturing and marketing of pharmaceutical products. The company manufactures and markets capsules, tablets, granules, and injections for the treatment of cancer and other diseases. The company operates two businesses: the Pharmaceutical Business and the Consumer Healthcare Business.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Taiho is heavily invested in research and development, focusing on creating innovative and reliable drugs for patients awaiting new treatments. The company's strength lies in its ability to create new drugs using its unique drug discovery platforms. Taiho plays a significant role within the Otsuka group, particularly in oncology, and is dedicated to creating therapeutics for significant unmet needs such as cancers with brain metastasis and those with RAS mutations. The company is also advancing drug discovery research in the area of immune-related diseases by applying technologies emerging from its cancer research. Taiho is also pursuing global research collaboration and has built its own network with biotech ventures and academia to obtain innovative drug-discovery technologies and drug seeds, to supplement its own technologies, and accelerate R&D. The company’s pipeline spans oncology, hematology, and select non-oncology indications. Its oncology programs target FGFR, EGFR, PI3K/AKT, HSP90, multikinase, PD-1/TIGIT, CD73, IAP and others across solid tumors and combinations (many in Phase I–II; TAS-115 and TAS6417 in Phase II/III). Hematology includes DNA methyltransferase and MDS/AML programs (Phase I–III). The company's non-oncology assets address DMD, rheumatoid arthritis, urticaria and urinary disorders (Phase II–III).